Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile

Posted: October 30, 2024 at 2:42 am

Ad hoc announcement pursuant to Art. 53 LR

See the article here:
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile

Related Posts